Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levodopa + carbidopa + entacapone (Orion Corporation)
- Development stage
- Phase 4
- Lead developer
- Orion
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dopacone is a fixed-dose combination medication containing levodopa (a dopamine precursor), carbidopa (a peripheral aromatic L-amino acid decarboxylase inhibitor), and entacapone (a selective, reversible catechol-O-methyltransferase inhibitor). It is indicated for the treatment of patients with Parkinson's disease who experience end-of-dose 'wearing-off' symptoms. Levodopa crosses the blood-brain barrier and is converted into dopamine to replenish deficient levels in the brain. Carbidopa prevents the peripheral breakdown of levodopa, reducing systemic side effects and increasing the amount of levodopa that reaches the brain. Entacapone further extends the half-life of levodopa by blocking its metabolism by catechol-O-methyltransferase (COMT) in peripheral tissues, ensuring more continuous and stable dopaminergic stimulation.
- Brand names
- Dopacone
- Other names
- carbidopa + entacapone + levodopacarbidopa + levodopa + entacaponecarbidopa, levodopa and entacaponelevodopa + entacapone + carbidopalevodopa, carbidopa and entacapone
02
Targets
DDC (Aromatic L-amino acid decarboxylase)COMT (Catechol-O-methyltransferase)DRD (Dopamine receptors)KEAP1 (Kelch-like ECH-associated protein 1)
Beyond the preview
Go deeper on levodopa + carbidopa + entacapone (Orion Corporation).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levodopa + carbidopa + entacapone (Orion Corporation).